Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, whereas semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP
If the starting question is simply "how much BAC water should I add?", use the Bac Water Calculator first
It is patented worldwide by BIOSINT SpA (58.5% l-carnitine, 41.5% fumaric acid, US patent number 4,602,039)
Individuals with type 2 diabetes and obesity face a high risk for developing cardiovascular disease and experiencing major cardiac events or conditions, including myocardial infarction, stroke, heart failure, cardiovascular death, and peripheral arterial disease